Skip to main content

Table 13 Other conditions

From: Benefits and harms of medical cannabis: a scoping review of systematic reviews

Author, year {refid} Search dates; # databases searched Funding source Nstudies Illness/condition Intervention/comparator* Outcomes Conclusions from data AMSTAR-2 rating
Huntley, 2000 [66] Inception to Dec 1999; 4 NR 1 Asthma I: Plant-derived cannabinoids
C: Placebo
• Airway resistance (raw) Only one study included M
Singh, 2007 [77] Inception to Dec 2004; 6 Non-profit 4 Asthma I: Plant-based cannabis
C: Placebo; isoproterenol; low-dose marijuana
• Pulmonary function test Reported SBS M
Snedecor, 2013 [70] To Jun 2011; 5 Industry 1 Diabetes I: Plant-derived cannabinoids
C: placebo
• Peripheral NP (mean reduction in pain)
• Peripheral NP (mean probability of 30% pain reduction)
Unclear efficacy (not enough information provided by authors) L
Norton, 2017 [28] Inception–Feb 2016; 5 NR 3 Inflammatory bowel disease I: Plant-based cannabis
C: No comparator (observational study)
N/A observational data N/A observational data CL
Langhorst, 2015 [44] Inception–Mar 12, 2014; 4 Non-profit 1 Inflammatory bowel disease (Crohn's, ulcerative colitis, IBS) I: Plant-based cannabis
C: Placebo cigarettes (THC removed)
• Response rate
• QoL
• Remission rate
Only one study included M
CADTH, 2014 [81] Jan 1, 1982 to Aug 8 2014; 5 NR 4 Nausea and vomiting (non-chemotherapy-induced) I: Synthetic cannabinoids
C: Metoclopramide
• Postoperative nausea and vomiting
• Patient rating of nausea and vomiting (VAS)
Only one study included L
  1. CADTH Canadian Agency for Drugs and Technologies in Health, IBS irritable bowel syndrome, NR not reported, QoL quality of life, SBS study-by-study, VAS visual analog scale
  2. *A colon indicates that there were separate analyses for each comparator